Trial Profile

A Phase 2 Clinical Trial to Investigate the Effectiveness of MYMD-1 to Treat Immune Mediated Depression in Patients Affected with COVID

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jul 2024 According to TNF Pharmaceuticals media release, MyMD Pharmaceuticals, Inc changed its name to TNF Pharmaceuticals, Inc.
05 Oct 2021 According to a MyMD Pharmaceuticals media release, company will give details of this trial at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7, 2021.
05 Aug 2021 According to a MyMD Pharmaceuticals media release, Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation expected to begin by fourth quarter 2021.Initial trial data expected in first quarter 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com